TMS Combined With EEG/EMG as a Biomarker Predicting Antiepileptic Drug Response

Focal Epilepsy Clinical Trial

— BIOEPI  

Official title:

Development and Optimization of Transcranial Magnetic Stimulation (TMS) Combined With EEG/EMG as a Biomarker Predicting Response to Antiepileptic Drugs

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05278221
• Other study ID #: BIOEPI
• Status: Recruiting
• Phase: N/A
• Start date: August 1, 2022
• Est. completion date: March 31, 2024

Study information

• Verified date: March 2023
• Source: Aristotle University Of Thessaloniki
• Contact: Vasilios Kimiskidis, Professor
• Phone: +30-2310-994667
• Email: kimiskid[@]auth.gr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Ιn the present study (BIOEPI), the following three hypotheses will be investigated: 1. The proposed TMS-EEG / EMG protocol (which includes software for calculating the cerebral cortex stimulation threshold) in combination with advanced signal analysis and data mining methods will allow the detection of the effect of antiepileptic drugs (AED) with different mechanisms of action (lacosamide & brivaracetam) in the Central Nervous System under healthy and pathological conditions (Epilepsy). 2. AED-induced changes in selected TMS-EEG / EMG features predict the clinical response of individual epileptic patients to AED. 3. AED-induced changes in selected TMS-EEG / EMG features may predict cognitive side effects.

Description:

The overarching objective of this study is to develop a combined TMS-EEG/EMG protocol so as to explore the effects of AEDs on cortical excitability and obtain novel electrophysiological biomarkers which could help predict the response of epileptic patients to AEDs, in line with the principles of personalized medicine. In order to achieve the overarching objective, we will perform a Diagnostic Clinical Performance Study, (FDA 2013) with the following specific objectives. Primary Objective 1: To investigate whether TMS-EEG/EMG biomarkers can predict the response of patients with focal epilepsy to AEDs (Lacosamide & Brivaracetam). Secondary Objective 1: Development, testing and validation of novel TMS-EEG/EMG stimulation and multi-level data analysis protocols, incorporating advanced methods of signal analysis, connectivity, complexity, and propagation across the cortical mantle. Secondary Objective 2: Investigating the sensitivity of TMS-EEG/EMG biomarkers for detecting changes in brain physiology in healthy subjects and patients with focal epilepsy.Secondary Objective 3: Investigating whether TMS-EEG / EMG biomarkers may predict cognitive deficits in patients with focal epilepsy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 42
• Est. completion date: March 31, 2024
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

General criteria:

1. Adult volunteers aged 18-65 years

2. Able to provide informed consent

3. Meet the criteria of the attached TMS safety questionnaire (Rossi et al, 2011). It is clarified that: a) criterion 1 does not apply to the group of patients and b) a positive answer to criteria 5, 6, 8, 9 & 10 excludes inclusion in the study while the other answers are evaluated by the investigator. Specific criteria: The specific criteria per group of study participants are as follows:

Patient Group:

1. Adult patients, 18-65 years of age, suffering from focal epilepsy, as evidenced by clinical and EEG features.

2. All patients continue suffering from seizures despite treatment with 1-2 concomitant AEDs (with vagal nerve stimulation counting as an AED). In order to be eligible, patients should be suffering from simple partial seizures (SPS) and a motor component or complex partial seizures (CPS) with or without secondary generalization (sGS). Patients should report at least three seizures during the 12 weeks of Historical Baseline.

3. Patients are required to be Lacosamide and Brivaracetam-naive and, in the latter case, not taking concomitant Levetiracetam.

4. Patients are about to commence treatment with Lacosamide or Brivaracetam, as per the treating physician's orders. It is stressed that the decision to prescribe Lacosamide or Brivaracetam is made by the patient's treating physician totally independently from participation in the current study.

5. Epilepsies of genetic or unknown aetiology (patients with hippocampal sclerosis can be included). The epileptic patients will be a convenience sample recruited at the Epilepsy Outpatient Clinic of the University General Hospital of Thessaloniki "AHEPA". Healthy control group: Adult, healthy volunteers, 18-65 years of age Exclusion Criteria: The specific criteria per group of study participants are as follows:

Patient Group:

1. The presence of Central Nervous System "CNS" disorders other than epilepsy on history or examination

2. Comorbid psychiatric or medical conditions that may compromise the ability of the individuals to participate in the study

3. EEG evidence of generalized epilepsy.

4. Uncountable seizures due to clustering.

5. Use of centrally acting drugs other than AEDs.

6. Pregnancy or planned pregnancy prior to the index test.

Healthy control group:

1. Presence of medical or psychiatric conditions that may interfere with the procedures.

2. Contraindications to TMS (i.e. pregnancy, presence of heart pacemakers, metal objects etc).

3. History of adverse reactions to pharmacological agents.

4. History of alcohol or nicotine abuse or use of any other centrally acting drug.

5. Participation in another clinical trial in the previous 8 weeks.

6. Pregnancy or planned pregnancy prior to the index test.

Related Conditions & MeSH terms

• Epilepsies, Partial
• Epilepsy
• Focal Epilepsy

Intervention

Device:
• Software EstimLT
Healthy volunteers will receive a single per os dose of Lacosamide (200 mg), Brivaracetam (50 mg) or placebo and then the software will be tested

Locations

Country	Name	City	State
Greece	Prof. Vasilios Kimiskidis	Thessaloníki	Thessaloniki

Sponsors (1)

Lead Sponsor	Collaborator
Aristotle University Of Thessaloniki

Country where clinical trial is conducted

Greece, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Diagnostic accuracy of TMS Combined With EEG/EMG for predicting response to AEDs	The Primary Outcome Measure is the diagnostic accuracy (calculated as the number of true positives + true negatives)/(number of true positives + true negatives + false positives + false negatives) of the index test for predicting response to AEDs (defined as reduction of seizure frequency by 50% or more during the maintenance period in comparison to baseline).; The primary efficacy endpoint will be assessed in the combined groups of responders (LAC+BRV) and non-responders (LAC+BRV) because the starting hypothesis is that response to AEDs will be associated with alterations in TMS-EEG/EMG biomarkers.	9 months
Secondary	PPV, NPV, LR+ & LR- of TMS Combined With EEG/EMG for predicting response to AEDs	Positive Predictive Value (PPV), Negative Predictive Value (NPV), positive likelihood ratio (LR+) & negative likelihood ratio (LR-) of TMS Combined With EEG/EMG for predicting response to AEDs (defined as reduction of seizure frequency by 50% or more).	Through study completion, an average of 2 years
Secondary	Accuracy, PPV, NPV, LR+ & LR- of TMS Combined With EEG/EMG for other measures of response to AEDs	Accuracy, PPV, NPV, positive likelihood ratio (LR+) & negative likelihood ratio (LR-) of TMS Combined With EEG/EMG for other measures of response to AEDs (i.e. percent seizure reduction, seizure freedom, time to n th (n=1,5th,10th) seizure).	Through study completion, an average of 2 years
Secondary	Accuracy of TMS Combined With EEG/EMG for predicting AED-induced side-effects	Accuracy of TMS Combined With EEG/EMG for predicting AED-induced cognitive side-effects and other study-emergent Adverse Events	Through study completion, an average of 2 years